Edition:
United States

Insmed Inc (INSM.O)

INSM.O on Nasdaq

30.33USD
17 Nov 2017
Change (% chg)

$-0.60 (-1.94%)
Prev Close
$30.93
Open
$30.75
Day's High
$30.94
Day's Low
$29.92
Volume
374,862
Avg. Vol
1,210,492
52-wk High
$32.94
52-wk Low
$11.49

Chart for

About

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment... (more)

Overall

Beta: 1.15
Market Cap(Mil.): $2,323.00
Shares Outstanding(Mil.): 76.59
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-Insmed Q3 loss per share $0.69

* Insmed reports third quarter 2017 financial results and provides business update

Nov 02 2017

BRIEF-Arsanis appoints Michael Gray as chief financial officer

* Arsanis announces appointments of Chip Clark and David Mcgirr to board of directors and promotion of Michael Gray to chief operating officer and chief financial officer Source text for Eikon: Further company coverage:

Oct 04 2017

BRIEF-Insmed announces proposed public offering of common stock

* Insmed Inc - ‍Has commenced an underwritten public offering of $250 million of shares of its common stock​

Sep 05 2017

Insmed shares skyrocket after lung drug meets key study's main goal

Shares of Insmed Inc more than doubled on Tuesday after the company said its drug to treat adults with a rare lung disorder met the main goal in a key study, leading it to apply for accelerated approval.

Sep 05 2017

UPDATE 2-Insmed shares skyrocket after lung drug meets key study's main goal

* Shares soar as much as 140 pct (Adds details, analyst comments, updates shares)

Sep 05 2017

Insmed's lung drug meets main goal in late-stage study

Sept 5 Insmed Inc said its drug for the treatment of a rare and serious lung disorder met the main goal in a late-stage study, sending its shares up 75 percent in premarket trading on Tuesday.

Sep 05 2017

BRIEF-Insmed announces positive top-line results from phase 3 convert study of ALIS

* Insmed announces positive top-line results from phase 3 convert study of ALIS (amikacin liposome inhalation suspension) in adult patients with treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by mycobacterium avium complex (MAC)

Sep 05 2017

BRIEF-Insmed reports Q2 loss per share $0.72

* Insmed reports second quarter 2017 financial results and provides business update

Aug 03 2017

Competitors

Earnings vs. Estimates